Loading contract…
BETAThis is a new independent transparency project, not an official government website. The data is sourced from public registers and may contain errors, so always verify against the official source. If you find a problem, please report it here.
One or more suppliers on this contract have also made political donations. See supplier details below.
Vaccines have been shown to be highly effective in the fight against COVID-19, to date. However, there is a cohort of individuals who either cannot take the vaccine or for whom it is ineffective. There is therefore an urgent need to find an effective alternative. So far there are no primary care antiviral drugs that can be easily dispensed specifically to treat SARS-CoV-2 and prevent its transmission in the community.
This agreement is for the procurement of 250,000 units of PF-07321332/ritonavir . It is one of the first oral and direct-acting antiviral drugs globally and is part of the UK's multi-layered approach to COVID-19.
| Supplier | Identifier | Award Value | Cross-References |
|---|---|---|---|
| Pfizer Limited | 00526209 | £1 | DONOR£41K across 4 donations To: Progressive Britain Ltd (formally Progress Ltd) LOBBYIST Portland PR Limited (20 quarters) Hanover Communications International Limited (3 quarters) Ovid Consulting Ltd (3 quarters) Incisive Health Ltd (1 quarter) MHP Communications (1 quarter) FORMER MP John Austin— Gifts, benefits and hospitality from UK sources (former) |
Government spending data: This supplier has received £205,888,548 in 73 payments (over £25k) from UK Health Security Agency, Department of Health and Social Care, NHS England, Ministry of Defence (2019-01-21 to 2026-03-12). View full payment history →